Stock Report

All about this stock under one free report Last Updated: 27-Aug-2026

Stock Rating

See the stock’s health at a glance, before it's too late.

Wealth Insight New Issue

This month’s issue could change how you invest, read now.

Recently Viewed

Clear All

Aarey Drugs Peer Comparison

Stock Card factsheet watchlist-stock-modal share-fund-plan-icon

NSE: AAREYDRUGS | BSE: 524412

₹84.78

up-down-arrow ₹4.03 (4.99%)

As on 27-Aug-2026 15:58IST

Market cap

info icon

₹262 Cr

Revenue (TTM)

info icon

₹415 Cr

P/E Ratio

info icon

62.8

P/B Ratio

info icon

1.6

Div. Yield

info icon

0 %

Edit peer-selector-edit
Aarey Drugs Wockhardt Rubicon Research Piramal Pharma Acutaas Chemicals
Market cap (₹ Cr)
 262 31,881 30,600 28,584 27,230
Revenue (₹ Cr)
 415 3,564 1,936 9,205 1,462
Net Profit (₹ Cr)
 4.18 414.00 288.22 -371.81 387.35
Net Margin (%)
 0.99 11.23 14.79 -3.93 26.01
RoE (%)
 2.79 8.38 29.77 -3.85 25.18
Price to Earnings
 62.78 77.95 106.17 -- 70.50
Price-To-Book
 1.60 6.33 22.80 3.57 15.75

Income Statement (₹ Cr)

Aarey Drugs Wockhardt Rubicon Research Piramal Pharma Acutaas Chemicals
Operating Revenue arrow
414.69 3,564.00 1,935.80 9,205.28 1,461.80
Total Income arrow
420.95 3,686.00 1,948.58 9,449.59 1,489.25
Total Expenditure arrow
407.89 2,792.00 1,485.56 8,195.15 919.25
EBITDA arrow
6.80 772.00 450.24 1,010.13 542.56
Depreciation arrow
3.22 226.00 50.83 857.51 37.68
EBIT arrow
3.58 546.00 399.41 152.62 504.88
Interest arrow
5.64 217.00 40.84 342.73 3.77
Other Income arrow
6.26 122.00 12.78 244.31 27.45
Exceptional Items arrow
0.00 12.00 0.00 -216.88 0.00
Profit before Tax arrow
4.20 463.00 371.35 -162.68 528.56
Provision for Tax arrow
0.03 49.00 83.14 209.13 141.21
Profit after Tax arrow
4.18 414.00 288.22 -371.81 387.35

Liabilities (₹ Cr)

Aarey Drugs Wockhardt Rubicon Research Piramal Pharma Acutaas Chemicals
Shareholder's Funds arrow
150.42 4,940.00 1,288.82 8,162.62 1,653.56
Minority Interest arrow
0.00 -5.00 0.00 0.00 -1.13
Non-Current Liabilities arrow
1.75 1,712.00 202.03 5,044.14 42.40
Current Liabilities arrow
145.08 1,622.00 835.87 4,758.28 230.82
Total Liabilities arrow
290.59 8,100.00 1,451.43 15,513.53 1,549.26

Assets (₹ Cr)

Aarey Drugs Wockhardt Rubicon Research Piramal Pharma Acutaas Chemicals
Non-Current Assets arrow
27.89 5,343.00 519.60 10,211.52 1,026.85
Current Assets arrow
262.94 2,606.00 1,681.81 7,191.66 881.27
Total Assets arrow
290.59 8,100.00 1,451.43 15,513.53 1,549.26
Total Debt* arrow
34.86 1,859.00 393.17 4,720.27 8.18
Net Current Assets arrow
117.87 984.00 845.94 2,433.38 650.46
Contingent Liabilities arrow
-- 770.26 12.25 99.76 15.38

Cashflow (₹ Cr)

Aarey Drugs Wockhardt Rubicon Research Piramal Pharma Acutaas Chemicals
Cash From Operating Activities arrow
10.30 -22.00 159.18 892.30 118.34
Cash Flow from Investing Activities arrow
-5.94 -783.00 -64.81 -477.46 -223.94
Cash from Financing Activities arrow
-4.48 409.00 -39.81 -440.83 261.12
Net Cash Inflow / Outflow arrow
-0.12 -396.00 54.56 -25.99 155.52

Ratios

Profitability Ratios

 Aarey Drugs Wockhardt Rubicon Research Piramal Pharma Acutaas Chemicals
ROCE (%) arrow
6.38 4.07 26.97 6.61 20.14
ROE (%) arrow
2.79 8.38 29.77 -3.85 25.18
ROA (%) arrow
1.42 4.94 24.77 -2.21 21.93
EBIT Margin (%) arrow
0.86 15.32 20.63 1.66 34.54
Net Margin (%) arrow
0.99 11.23 14.79 -3.93 26.01
Cash Profit Margin (%) arrow
0.00 0.00 0.00 0.00 0.00

Growth Ratios

 Aarey Drugs Wockhardt Rubicon Research Piramal Pharma Acutaas Chemicals
Revenue Growth (%) arrow
-7.69 18.37 46.65 0.78 40.90
EBIT Growth (%) arrow
146.05 252.26 62.13 -70.53 124.50
Net Profit Growth (%) arrow
0.51 377.85 89.49 -1,383.43 104.15
EPS Growth (%) arrow
-0.04 1,001.33 78.60 -484.84 42.32
Book Value Growth (%) arrow
4.34 29.77 42.49 2.28 94.96

Valuation Ratios

 Aarey Drugs Wockhardt Rubicon Research Piramal Pharma Acutaas Chemicals
Price / Earnings arrow
54.92 76.67 102.64 -89.97 69.15
Price / Book Value arrow
1.53 6.07 22.38 3.52 15.45
Dividend Yield (%) arrow
0.00 0.00 0.08 0.00 0.08
EV/EBITDA arrow
41.66 41.47 66.53 31.97 48.78
Market Cap (₹ Cr) arrow
95.93 23,064.69 0.00 29,731.27 19,988.69

Solvency Ratios

 Aarey Drugs Wockhardt Rubicon Research Piramal Pharma Acutaas Chemicals
Debt to Equity arrow
0.01 0.31 0.11 0.53 0.01
Short term debt to equity ratio arrow
0.24 0.11 0.54 0.12 0.02
Current Ratio arrow
1.81 1.61 2.01 1.51 3.82
Quick Ratio arrow
1.53 1.06 1.14 0.87 2.82
Interest Coverage arrow
1.75 3.13 10.09 0.53 141.16

Operating Efficiency Ratios

 Aarey Drugs Wockhardt Rubicon Research Piramal Pharma Acutaas Chemicals
Debtors to sales (%) arrow
31.27 16.50 26.28 23.44 24.80
Asset Turnover arrow
1.41 0.43 1.66 0.55 0.83
Receivable days arrow
122.43 60.36 47.59 77.05 90.06
Inventory Days arrow
30.87 64.42 62.58 77.13 61.02
Payable days arrow
93.08 218.94 228.78 173.49 96.06
Cash Conversion Cycle arrow
60.21 -94.15 -118.62 -19.30 55.02
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
loading...
loading...
loading...